back to US directory
us clinical guidance

Established axial spondyloarthritis: treatment

The 2026 ACR treatment update for established axial spondyloarthritis; diagnosis and sacroiliac imaging remain an explicit source gap.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with confirmed radiographic or nonradiographic axial spondyloarthritis. The 2026 ACR/SAA/SPARTAN source is a treatment update and does not establish case-finding, diagnostic classification or sacroiliac-imaging criteria. Suspected but unconfirmed disease, juvenile disease, peripheral-dominant psoriatic arthritis and acute septic sacroiliitis require separate pathways.
sources for this section:ACR axSpA

The Bottom Line

  • Do not infer a case-finding rule or diagnostic threshold from this treatment update; suspected disease requires an exact current diagnostic authority and specialist assessment.
  • Do not infer when to order or how to interpret sacroiliac radiographs, MRI, HLA-B27 or inflammatory markers from this treatment source; those operational diagnostic claims remain blocked.
  • Prescribe regular exercise and physical therapy as core treatment and use NSAIDs when appropriate, balancing gastrointestinal, kidney and cardiovascular risk.
  • For active disease despite nonpharmacologic care and NSAIDs, select TNF, IL-17 or other advanced therapy from phenotype, prior response, uveitis, inflammatory bowel disease, infection risk and the 2026 recommendation sequence.
  • Avoid long-term systemic glucocorticoids for axial disease and do not treat spinal symptoms with conventional synthetic DMARDs that lack axial efficacy merely to satisfy a generic arthritis pathway.
sources for this section:ACR axSpA

Practical clinical workflow

1
For established disease, document current axial and peripheral activity, function, exercise, prior NSAID and advanced-therapy response, uveitis, psoriasis and inflammatory bowel disease.
2
Confirm the documented diagnosis and treatment phenotype before applying the ACR update; a diagnostic or imaging question must leave this workflow for an exact current diagnostic source.
3
Review treatment goals, contraindications and extra-articular disease with rheumatology rather than using the treatment update to retrospectively validate an uncertain diagnosis.
4
Start individualized exercise and NSAID treatment, assess disease activity and function with validated measures and escalate persistent active disease using the 2026 source.
5
Before advanced therapy, screen tuberculosis and hepatitis, update vaccines and review recurrent infection, IBD, uveitis, pregnancy and cardiovascular or malignancy risk.
sources for this section:ACR axSpA

Safety boundaries and escalation

  • Acutely severe focal spinal pain with fever, neurologic deficit or immunosuppression requires urgent infection or compression assessment rather than routine spondyloarthritis imaging.
  • A painful red photophobic eye can be acute anterior uveitis and needs urgent ophthalmology review to protect vision.
  • New neurologic signs after even minor trauma in an ankylosed spine can represent an unstable fracture and require emergency spinal imaging.
  • Biologics and targeted therapies have class- and product-specific infection, malignancy, cardiovascular, thrombosis or IBD cautions; check current FDA labeling.
sources for this section:ACR axSpA

Localization

The June 2026 ACR/SAA/SPARTAN adult update is used only for treatment of established disease. It does not establish a US diagnostic or imaging pathway.
sources for this section:ACR axSpA

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American College of Rheumatology, Spondylitis Association of America, and SPARTAN2026 Update of Recommendations for the Treatment of Axial Spondyloarthritis in Adults2026 adult update 路 published 2026-06-24 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.